Free Trial
NASDAQ:DWTX

Dogwood Therapeutics (DWTX) Stock Price, News & Analysis

Dogwood Therapeutics logo
$5.02 -0.34 (-6.34%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$4.96 -0.06 (-1.20%)
As of 05/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dogwood Therapeutics Stock (NASDAQ:DWTX)

Key Stats

Today's Range
$4.90
$5.45
50-Day Range
$2.94
$11.13
52-Week Range
$1.62
$29.28
Volume
153,488 shs
Average Volume
1.95 million shs
Market Capitalization
$9.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

DWTX MarketRank™: 

Dogwood Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dogwood Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Dogwood Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Dogwood Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dogwood Therapeutics are expected to grow in the coming year, from ($6.43) to ($4.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dogwood Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dogwood Therapeutics is -0.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dogwood Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dogwood Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for DWTX.
  • Dividend Yield

    Dogwood Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dogwood Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for DWTX.
  • News Sentiment

    Dogwood Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Dogwood Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 8 people have searched for DWTX on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Dogwood Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.20% of the stock of Dogwood Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.05% of the stock of Dogwood Therapeutics is held by institutions.

  • Read more about Dogwood Therapeutics' insider trading history.
Receive DWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DWTX Stock News Headlines

Brokers Set Expectations for DWTX Q1 Earnings
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Dogwood receives Nasdaq confirmation of compliance
Dogwood management to meet with Maxim
See More Headlines

DWTX Stock Analysis - Frequently Asked Questions

Dogwood Therapeutics' stock was trading at $2.49 at the beginning of the year. Since then, DWTX shares have increased by 101.6% and is now trading at $5.02.
View the best growth stocks for 2025 here
.

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) posted its quarterly earnings data on Monday, March, 31st. The company reported ($6.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by $4.80.

Shares of Dogwood Therapeutics reverse split on Wednesday, October 9th 2024. The 1-25 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional shareholders of Dogwood Therapeutics include FNY Investment Advisers LLC (0.65%).

Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/31/2025
Today
5/03/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DWTX
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+99.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.94 per share
Price / Book
1.02

Miscellaneous

Free Float
1,169,000
Market Cap
$9.59 million
Optionable
N/A
Beta
1.99
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:DWTX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners